Clinical Trials · NCT03730662
A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 2,002
- Start date
- Nov 2018
- Locations
- 216 sites, 15 countries
- Primary endpoint
- Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg)